Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1757-6512

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway ; volume:13 ; number:1 ; day:3 ; month:6 ; year:2022 ; pages:1-16 ; date:12.2022
Stem cell research & therapy ; 13, Heft 1 (3.6.2022), 1-16, 12.2022

Creator: Takao, Tomoka
Masuda, Hirotaka
Kajitani, Takashi
Miki, Fumie
Miyazaki, Kaoru
Yoshimasa, Yushi
Katakura, Satomi
Tomisato, Shoko
Uchida, Sayaka
Uchida, Hiroshi
Tanaka, Mamoru
Maruyama, Tetsuo

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13287-022-02888-y

URN: urn:nbn:de:101:1-2022080222121330943103

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Takao, Tomoka
Masuda, Hirotaka
Kajitani, Takashi
Miki, Fumie
Miyazaki, Kaoru
Yoshimasa, Yushi
Katakura, Satomi
Tomisato, Shoko
Uchida, Sayaka
Uchida, Hiroshi
Tanaka, Mamoru
Maruyama, Tetsuo
SpringerLink (Online service)

Other Objects (12)

DOCK1 regulates the malignant biological behavior of endometrial cancer through c-Raf/ERK pathway

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways

Hochschulschrift

PI3K-Akt and Raf-MEK-ERK signalling in adipocytes

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

Hochschulschrift

The role of oncogenic B-Raf in different aspects of malignant transformation

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

DOCK1 regulates the malignant biological behavior of endometrial cancer through c-Raf/ERK pathway

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways

Hochschulschrift

PI3K-Akt and Raf-MEK-ERK signalling in adipocytes

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

Hochschulschrift

The role of oncogenic B-Raf in different aspects of malignant transformation

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

DOCK1 regulates the malignant biological behavior of endometrial cancer through c-Raf/ERK pathway

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways

Hochschulschrift

PI3K-Akt and Raf-MEK-ERK signalling in adipocytes

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

Hochschulschrift

The role of oncogenic B-Raf in different aspects of malignant transformation

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

DOCK1 regulates the malignant biological behavior of endometrial cancer through c-Raf/ERK pathway

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways

PI3K-Akt and Raf-MEK-ERK signalling in adipocytes

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

The role of oncogenic B-Raf in different aspects of malignant transformation

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

DOCK1 regulates the malignant biological behavior of endometrial cancer through c-Raf/ERK pathway

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways

PI3K-Akt and Raf-MEK-ERK signalling in adipocytes

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

The role of oncogenic B-Raf in different aspects of malignant transformation

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

DOCK1 regulates the malignant biological behavior of endometrial cancer through c-Raf/ERK pathway

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways

PI3K-Akt and Raf-MEK-ERK signalling in adipocytes

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation

Ribosomal protein L22-like1 (RPL22L1) mediates sorafenib sensitivity via ERK in hepatocellular carcinoma

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway

The role of oncogenic B-Raf in different aspects of malignant transformation

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

Sensitivity and resistance of oncogenic RAS-driven tumors to dual MEK and ERK inhibition

Related objects

Reset password